Precise to use Autonomy’s IDOL to boost media intelligence

Autonomy Corporation plc, specialists in infrastructure software for the enterprise, and media intelligence firm Precise announced a collaboration in which Precise will develop and market next-generation media intelligence services to the PR and communications sectors.

Precise will use Autonomy's Meaning Based Computing technology to boost its monitoring and analysis across the full media spectrum, including broadcast, print, web, social media and discussion forums.

Autonomy's core infrastructure software the Intelligent Data Operating Layer (IDOL) was selected for its ability to go beyond simple keyword search and provide conceptual capabilities, format and language independence and scalability.

The first phase of the project entails the implementation of Chorus, a new media intelligence workflow engine, which is delivering a step change in the speed, accuracy and depth of intelligence.  

IDOL delivers a computing platform which enables computers to see patterns in information the way people do. By identifying patterns and forming models to visualize and understand them, Autonomy enables organizations to quickly spot and act on trends.

Chorus enables Precise to assess the relevance and impact of news and comment, automatically and in real-time, so that PR and communications activity can be targeted more quickly and effectively.

Next-generation functionality, such as advanced analytics, automatic tagging and classification and sentiment analysis enable Precise to offer first-class analysis and monitoring capabilities across a vast array of news and social media content.

 



Previous articles
AVEVA rides the resource boom to record revenue, profit; plans share split
Silicon Fen shares the pain as £1.6 billion wiped off the value of top ten firms in past month
Cybit returns to profit in 1H; says performance continues to improve
Just five Silicon Fen high techs hold back the stock market red ink
AstraZeneca wraps up CAT; appoints new top management
Cambridge Consultants unveils novel prefilled syringe, cutting volume in half
AVEVA hits record results in 08/09; ‘better equipped’ to trade thru downturn
Acambis gains as its smallpox vaccine gets the nod from key FDA Advisory Committee
'A year of two halves' for BioProgress as 2H '05 costs slashed; sees maiden profits in '06
Brady boosts profit, revenue in 1H09; says ‘well placed’ for growth
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • Alizyme


Alan Goodman
Director


Alizyme plc is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focused on obesity and related diseases, such as diabetes, and on gastrointestinal disorders including irritable bowel syndrome, inflammatory

[Alizyme's profile]


Top20 Index




Currently: 129.81

Best Deal Mortgages
If debt is becoming a problem, click here for the best deal mortgages.

Marcus Evans
See why clients believe they get invaluable, focussed training from Marcus Evans.

Marcus Evans scam
Marcus Evans scam prevention conferences will help you to detect and deter fraud within your company.

International Ferro Metals
View the International Ferro Metals website for news, articles and presentations.